About US
Contact us
-
Pharma hikes prices on all sorts of meds, but hit diabetes hardest: BloombergHere are more stats for the price-increase tally: Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years,Bloombergreports. Once again,2015/5/7
-
Hampton steps into GSK chairman role as discontent with Witty buildsGlaxoSmithKline's ($GSK) new chairman has his work cut out for him. The British drugmaker has sluggish sales in the U.S. and revenue growth that falls behind that of its Big Pharma rivals. It also rec2015/5/6
-
Zoetis, under pressure from activist investor Ackman, will offload 10 plants to cut costsAnimal health leader Zoetis ($ZTS) is using a move out of the Amgen ($AMGN) playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor. Zoetis announced in its first-2015/5/6
-
Prepping for spendy launches, pharma execs take a hint from Gilead's pricing fightAs payers continue to flex their drug-pricing muscles, it's more important for drugmakers to land on their good sides--especially as companies prepare to roll pricey treatments onto the market. And ph2015/5/5
-
WuXi starts up construction of China's largest biologics plantWuXi Biologics is embarking on construction of a new manufacturing facility that will be the biggest biologics plant inChina. It'll also be the world's largest facility for mammalian cell culture manu2015/5/5
-
Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spendIt's a good thing for Medicare that AstraZeneca's ($AZN)Nexiumhas gone generic and Teva's ($TEVA)Copaxoneis headed that way. That is because they are among about 10% of the drugs covered by Medicare w2015/5/4
-
GSK weighing scrapping investor payout to boost dividend insteadAnalysts are suggesting that GlaxoSmithKline ($GSK) is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis2015/5/4
-
Express Scripts: Fight against cancer drug prices 'much bigger' than hep CExpress Scripts ($ESRX) has been warning about a crackdown on cancer drug spending. Now, it's talking about how. The good news for pharma: It's not going to be a quick-hit, drama-filled operation lik2015/4/30
-
Ex-Sanofi exec Whitaker lands at Valeant in EVP roleSanofi's ($SNY) former North American pharma president, Anne Whitaker, has found yet another new place to call home. After departing from the French drug giant last year for the CEO's chair at Synta P2015/4/30
-
Mylan recalls injectable cancer meds, most produced for PfizerTop of mind for Mylan ($MYL) may be fending off an unsolicited $40 billion buyout offer from competitor Teva ($TEVA), but it still has to take care of business as usual. Right now that includes recall2015/4/29